Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection

INTRODUCTION: Direct-acting antivirals (DAAs) represent a breakthrough in hepatitis C virus (HCV) treatment as they directly inhibit HCV nonstructural (NS) proteins (NS3/4A, NS5A, and NS5B). However, ongoing debates exist regarding their relationship with hepatocellular carcinoma (HCC) whose inciden...

Descripción completa

Detalles Bibliográficos
Autores principales: Zidan, Ahmad M., Saad, Eman A., Ibrahim, Nasser E., Hashem, Medhat H., Mahmoud, Amal, Hemeida, Alaa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113831/
https://www.ncbi.nlm.nih.gov/pubmed/34013078
http://dx.doi.org/10.1016/j.heliyon.2021.e06908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113831/
https://www.ncbi.nlm.nih.gov/pubmed/34013078
http://dx.doi.org/10.1016/j.heliyon.2021.e06908

Ejemplares similares